179 related articles for article (PubMed ID: 35461033)
21. The impact of COVID-19 on diagnostic biomarkers in neuropsychiatric and neuroimmunological diseases: a review.
Dadkhah M; Talei S; Doostkamel D; Molaei S; Rezaei N
Rev Neurosci; 2022 Jan; 33(1):79-92. PubMed ID: 34087964
[TBL] [Abstract][Full Text] [Related]
22. Intensive care for seriously ill patients affected by novel coronavirus sars - CoV - 2: Experience of the Crema Hospital, Italy.
Zuccon W; Comassi P; Adriani L; Bergamaschini G; Bertin E; Borromeo R; Corti S; De Petri F; Dolci F; Galmozzi A; Gigliotti A; Gualdoni L; Guerra C; Khosthiova A; Leati G; Lupi G; Moscato P; Perotti V; Piantelli M; Ruini A; Sportelli S; Susca M; Troiano C; Benelli G; Buscarini E; Canetta C; Merli G; Scartabellati A; Melilli B S C G; Sfogliarini R; Pellegatta G; Viganò G
Am J Emerg Med; 2021 Jul; 45():156-161. PubMed ID: 33046317
[TBL] [Abstract][Full Text] [Related]
23. COVID-19 and Headache Medicine: A Narrative Review of Non-Steroidal Anti-Inflammatory Drug (NSAID) and Corticosteroid Use.
Arca KN; Smith JH; Chiang CC; Starling AJ; Robertson CE; Halker Singh RB; Schwedt TJ; Kissoon NR; Garza I; Rozen TD; Boes CJ; Whealy MA; VanderPluym JH
Headache; 2020 Sep; 60(8):1558-1568. PubMed ID: 32648592
[TBL] [Abstract][Full Text] [Related]
24. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).
Shanmugaraj B; Siriwattananon K; Wangkanont K; Phoolcharoen W
Asian Pac J Allergy Immunol; 2020 Mar; 38(1):10-18. PubMed ID: 32134278
[TBL] [Abstract][Full Text] [Related]
25. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
26. A Recent Achievement in the Discovery and Development of Vaccines and Therapeutic Agents in the Race for COVID-19 Protection and Treatment.
Kifle ZD; Enyew EF; Mekuria AB
J Evid Based Integr Med; 2021; 26():2515690X211003727. PubMed ID: 33761791
[TBL] [Abstract][Full Text] [Related]
27. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
Wooding DJ; Bach H
Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
[TBL] [Abstract][Full Text] [Related]
28. Neurotropism and Neuropsychiatric Symptomsi in Patients with COVID-19.
Moretti P; Brufani F; Pierotti V; Pomili G; Di Buò A; Giulietti C; Masini F; Tanku V; Bachetti MC; Menculini G; Tortorella A
Psychiatr Danub; 2021 Dec; 33(Suppl 11):10-13. PubMed ID: 34862882
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
30. Rapid and sensitive diagnostic procedure for multiple detection of pandemic Coronaviridae family members SARS-CoV-2, SARS-CoV, MERS-CoV and HCoV: a translational research and cooperation between the Phan Chau Trinh University in Vietnam and University of Bari "Aldo Moro" in Italy.
Pham VH; Gargiulo Isacco C; Nguyen KCD; Le SH; Tran DK; Nguyen QV; Pham HT; Aityan S; Pham ST; Cantore S; Inchingolo AM; Inchingolo AD; Dipalma G; Ballini A; Inchingolo F
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):7173-7191. PubMed ID: 32633414
[TBL] [Abstract][Full Text] [Related]
31. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms.
Troyer EA; Kohn JN; Hong S
Brain Behav Immun; 2020 Jul; 87():34-39. PubMed ID: 32298803
[TBL] [Abstract][Full Text] [Related]
32. Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose.
Doyno C; Sobieraj DM; Baker WL
Clin Toxicol (Phila); 2021 Jan; 59(1):12-23. PubMed ID: 32960100
[TBL] [Abstract][Full Text] [Related]
33. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
34. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
35. Pain management recommendations during the progression of SARS-CoV-2 infection.
Dhar A; Kachroo P; Herve M; Petruschke R
Pain Manag; 2023 Jan; 13(1):61-69. PubMed ID: 36515014
[TBL] [Abstract][Full Text] [Related]
36. SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic.
Fuereder T; Berghoff AS; Heller G; Haslacher H; Perkmann T; Strassl R; Berger JM; Puhr HC; Kreminger J; Moik F; Schubert L; Starzer AM; Steindl A; Winkler S; Preusser M; Tobudic S
ESMO Open; 2020 Sep; 5(5):e000889. PubMed ID: 32878898
[TBL] [Abstract][Full Text] [Related]
37. Emerging coronaviruses: first SARS, second MERS and third SARS-CoV-2: epidemiological updates of COVID-19.
Halaji M; Farahani A; Ranjbar R; Heiat M; Dehkordi FS
Infez Med; 2020 Jun; 28(suppl 1):6-17. PubMed ID: 32532933
[TBL] [Abstract][Full Text] [Related]
38. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
Abdurrahman L; Fang X; Zhang Y
Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
[TBL] [Abstract][Full Text] [Related]
39. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
[TBL] [Abstract][Full Text] [Related]
40. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
